Logo image of NPCE

NEUROPACE INC (NPCE) Stock Price, Quote, News and Overview

NASDAQ:NPCE - Nasdaq - US6412881053 - Common Stock - Currency: USD

12.89  +0.34 (+2.71%)

After market: 12.89 0 (0%)

NPCE Quote, Performance and Key Statistics

NEUROPACE INC

NASDAQ:NPCE (5/9/2025, 8:12:00 PM)

After market: 12.89 0 (0%)

12.89

+0.34 (+2.71%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High15.11
52 Week Low5.45
Market Cap422.15M
Shares32.75M
Float23.74M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13/amc
IPO04-22 2021-04-22


NPCE short term performance overview.The bars show the price performance of NPCE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

NPCE long term performance overview.The bars show the price performance of NPCE in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of NPCE is 12.89 USD. In the past month the price increased by 21.15%. In the past year, price increased by 51.65%.

NEUROPACE INC / NPCE Daily stock chart

NPCE Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.87 231.08B
ISRG INTUITIVE SURGICAL INC 70.22 192.30B
BSX BOSTON SCIENTIFIC CORP 38.1 152.14B
SYK STRYKER CORP 30.4 145.39B
MDT MEDTRONIC PLC 15.63 107.07B
BDX BECTON DICKINSON AND CO 11.87 48.02B
EW EDWARDS LIFESCIENCES CORP 28.34 43.32B
IDXX IDEXX LABORATORIES INC 43.13 39.85B
RMD RESMED INC 26.99 35.93B
DXCM DEXCOM INC 51.32 33.20B
GEHC GE HEALTHCARE TECHNOLOGY 15.19 31.99B
PHG KONINKLIJKE PHILIPS NVR- NY 15.94 23.07B

About NPCE

Company Profile

NPCE logo image NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 184 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

Company Info

NEUROPACE INC

455 N. Bernardo Avenue

Mountain View CALIFORNIA US

CEO: Michael Favet

Employees: 179

NPCE Company Website

NPCE Investor Relations

Phone: 16502372700

NEUROPACE INC / NPCE FAQ

What is the stock price of NEUROPACE INC today?

The current stock price of NPCE is 12.89 USD. The price increased by 2.71% in the last trading session.


What is the ticker symbol for NEUROPACE INC stock?

The exchange symbol of NEUROPACE INC is NPCE and it is listed on the Nasdaq exchange.


On which exchange is NPCE stock listed?

NPCE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NEUROPACE INC stock?

13 analysts have analysed NPCE and the average price target is 17.19 USD. This implies a price increase of 33.39% is expected in the next year compared to the current price of 12.89. Check the NEUROPACE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NEUROPACE INC worth?

NEUROPACE INC (NPCE) has a market capitalization of 422.15M USD. This makes NPCE a Small Cap stock.


How many employees does NEUROPACE INC have?

NEUROPACE INC (NPCE) currently has 179 employees.


What are the support and resistance levels for NEUROPACE INC (NPCE) stock?

NEUROPACE INC (NPCE) has a support level at 12.88 and a resistance level at 13.96. Check the full technical report for a detailed analysis of NPCE support and resistance levels.


Is NEUROPACE INC (NPCE) expected to grow?

The Revenue of NEUROPACE INC (NPCE) is expected to grow by 17.66% in the next year. Check the estimates tab for more information on the NPCE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NEUROPACE INC (NPCE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NEUROPACE INC (NPCE) stock pay dividends?

NPCE does not pay a dividend.


When does NEUROPACE INC (NPCE) report earnings?

NEUROPACE INC (NPCE) will report earnings on 2025-05-13, after the market close.


What is the Price/Earnings (PE) ratio of NEUROPACE INC (NPCE)?

NEUROPACE INC (NPCE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).


What is the Short Interest ratio of NEUROPACE INC (NPCE) stock?

The outstanding short interest for NEUROPACE INC (NPCE) is 1.48% of its float. Check the ownership tab for more information on the NPCE short interest.


NPCE Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to NPCE. When comparing the yearly performance of all stocks, NPCE is one of the better performing stocks in the market, outperforming 92.4% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NPCE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to NPCE. Both the profitability and financial health of NPCE have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NPCE Financial Highlights

Over the last trailing twelve months NPCE reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 25.78% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.68%
ROE -338.71%
Debt/Equity 7.43
Chartmill High Growth Momentum
EPS Q2Q%21.74%
Sales Q2Q%19.18%
EPS 1Y (TTM)25.78%
Revenue 1Y (TTM)22.14%

NPCE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to NPCE. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 8.28% and a revenue growth 17.66% for NPCE


Ownership
Inst Owners58.03%
Ins Owners4.05%
Short Float %1.48%
Short Ratio1.37
Analysts
Analysts84.62
Price Target17.19 (33.36%)
EPS Next Y8.28%
Revenue Next Year17.66%